Avalyn Appoints Jon Congleton To Board
Avalyn Pharma Inc., a biopharmaceutical company focused on inhaled therapies for respiratory diseases, has appointed Jon Congleton to its Board of Directors. Congleton, CEO of Mineralys Therapeutics, brings nearly 40 years of biopharmaceutical experience and will help guide Avalyn's Phase 2 programs and commercialization efforts for its pulmonary fibrosis treatments. He expressed enthusiasm for Avalyn's potential to transform care given the limitations of existing treatments and the promising clinical data from its lead programs.
Mineralys Therapeutics (Nasdaq:MLYS) - Stock Analysis
This Simply Wall St Finstock analysis for Mineralys Therapeutics (MLYS) highlights the company's valuation, future growth, and financial health. MLYS is currently trading at a 44.5% discount to its estimated fair value of US$50.88, according to analyst consensus. The company, which is developing lorundrostat for hypertension, is unprofitable and has diluted shareholders in the past year, but analysts see strong long-term potential due to upcoming regulatory decisions and a large target population.
Daphne Karydas, director at Mineralys, sells $75,000 in MLYS stock By Investing.com
Daphne Karydas, a director at Mineralys Therapeutics Inc (MLYS), sold 3,000 shares of common stock for $75,000 and exercised options to acquire 3,000 shares for $36,060 through a pre-arranged trading plan. This transaction occurred as MLYS stock has shown significant momentum, returning 92.6% over the past year, although InvestingPro analysis suggests it may be overvalued despite high analyst price targets. The company recently exceeded Q4 2025 earnings expectations and is advancing its lead drug lorundrostat, alongside a new Chief Legal Officer appointment.
Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k
Mineralys Therapeutics, Inc. CEO Jon Congleton sold 75,000 shares of common stock on March 31, 2026, through a pre-arranged Rule 10b5-1 trading plan. The sales occurred at weighted-average prices between $25.50 and $27.05 per share. Following these transactions, Congleton's direct holdings in the company amount to 705,051 shares.
Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock By Investing.com
Mineralys Therapeutics CEO Jon Congleton sold 74,900 shares of MLYS stock worth $1.97 million on March 31, 2026, under a pre-arranged trading plan. Following the sale, Congleton still owns over 705,000 shares. This news comes amidst the company's recent positive Q4 2025 earnings beat, a new Chief Legal Officer appointment, and varied analyst price target adjustments for its lead drug, lorundrostat.
Insider Sell: CEO Jon Congleton Sells 75,000 Shares of Mineralys Therapeutics Inc (MLYS)
Mineralys Therapeutics Inc CEO Jon Congleton sold 75,000 shares of the company on March 31, 2026, reducing his holdings to 705,051 shares. This transaction is part of a larger trend of insider selling at Mineralys Therapeutics, with 32 insider sells versus 3 buys over the past year. Shares were trading at $26.27 each on the day of the sale, giving the company a market capitalization of $2.222 billion.
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells 3,000 Shares of Stock
Mineralys Therapeutics (NASDAQ:MLYS) Director Daphne Karydas sold 3,000 shares of the company's stock on March 31st for a total of $75,000, reducing her ownership by 32.61%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling, MLYS stock was up 2.1% at $26.97, and analysts have an average "Moderate Buy" rating with a target price of $49.14.
Mineralys Therapeutics (MLYS) director trades 3,000 shares under plan
Mineralys Therapeutics director Daphne Karydas exercised options to acquire 3,000 shares at $12.02 each, then immediately sold those 3,000 shares on the open market for $25.00 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025. Following these trades, Karydas directly holds 6,200 shares of common stock and 41,000 stock options.
Mineralys Therapeutics (NASDAQ:MLYS) Director Acquires $7,354,269.00 in Stock
A director at Mineralys Therapeutics (NASDAQ:MLYS), Ra Capital Management, L.P., recently acquired 310,700 shares of the company's stock for $7,354,269.00, increasing their total stake to 5,767,221 shares. The company's stock currently trades at $26.56, has a market capitalization of $2.19 billion, and analysts have a "Moderate Buy" consensus rating with an average target price of $49.14. Institutional investors hold approximately 84.46% of the company's stock.
Mineralys Therapeutics, Inc. (MLYS) stock price, news, quote and history
This Yahoo Finance page provides comprehensive information on Mineralys Therapeutics, Inc. (MLYS) stock, including its current price, historical data, key statistics, performance against benchmarks, and analyst insights. The company is a biopharmaceutical firm developing treatments for cardiorenal conditions, with its primary focus on lorundrostat. The data shows MLYS's positive one-year and three-year returns but negative YTD performance, alongside detailed financial metrics and comparisons with similar biotechnology companies.
Mineralys Therapeutics Surges on FDA Milestone Buzz
Mineralys Therapeutics (MLYS) stock is surging due to investor reaction to the FDA's acceptance of its New Drug Application for the hypertension drug lorundrostat, with a key decision date set for December 22, 2026. The company's recent hiring of a Chief Legal Officer to manage commercialization and regulatory strategy, coupled with growing institutional ownership, further reinforces the positive market sentiment. Investors believe lorundrostat could be a significant value driver for the company if approved.
Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress
Mineralys Therapeutics (MLYS) is gaining attention from hedge funds and analysts due to the progress of its lead drug, lorundrostat, for uncontrolled hypertension. Bank of America Securities increased its price target to $51, citing underappreciated peak sales potential. The company recently submitted its first NDA for lorundrostat, marking a significant regulatory achievement for the treatment of adult hypertension.
Mineralys Therapeutics (NASDAQ: MLYS) insider sells 3,000 shares
An insider at Mineralys Therapeutics (NASDAQ: MLYS) has filed a Form 144 to sell 3,000 shares of common stock, stemming from the exercise of employee stock options. The transaction, facilitated by Merrill Lynch as a broker-assisted cashless exercise on March 31, 2026, has an aggregate value of $75,000.00. This filing ensures transparency regarding the proposed sale.
Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares
Mineralys Therapeutics (MLYS) has filed a Form 144 indicating a proposed sale of 75,000 shares of common stock with an aggregate offering price of $1,970,520.69. The filing also notes 82,399,478 total shares outstanding as of March 31, 2026, and discloses recent vesting of restricted share units and a previous sale by Jon Congleton. This regulatory notice informs the broker and SEC of planned affiliate sales, with details on timing and actual execution expected in future trade notices.
RA Capital funds add 369,000 Mineralys (NASDAQ: MLYS) shares
RA Capital-managed funds have increased their stake in Mineralys Therapeutics (NASDAQ: MLYS) by purchasing a total of 369,000 shares in late March 2026. These open-market purchases were made at weighted average prices of $23.67 and $24.16 per share, signaling a very positive sentiment and material impact on the stock. Following these transactions, one fund held over 5.8 million shares, and another held over 1.8 million shares, with RA Capital Management, L.P. acting as the investment manager.
SG Americas Securities LLC Buys 130,758 Shares of Mineralys Therapeutics, Inc. $MLYS
SG Americas Securities LLC significantly increased its stake in Mineralys Therapeutics, Inc. by 130.7%, acquiring an additional 130,758 shares. The firm now holds 230,795 shares valued at $8.38 million. Despite recent insider selling, institutional investors maintain a substantial 84.46% ownership, and analysts generally rate the stock as a "Moderate Buy" with an average price target of $49.14.
Mineralys Therapeutics, Inc. - Common Stock (NQ: MLYS)
This article provides recent news and stock information for Mineralys Therapeutics, Inc. (MLYS). It highlights investor alerts regarding investigations into the company from law firms Bronstein, Gewirtz and Grossman, LLC, and the Schall Law Firm, dated September 2024. Additionally, it mentions a recent board expansion for Praxis Bioresearch and details from Mineralys' February 2023 IPO.
Mineralys reports 2025 results, advances hypertension drug review
Mineralys Therapeutics announced positive full-year 2025 financial results, reporting a net loss of $204.6 million and cash, cash equivalents, and marketable securities of $428.1 million. The company is advancing the New Drug Application (NDA) for its hypertension drug, lorundrostat, following a positive pre-NDA meeting with the FDA and plans to submit the NDA in mid-2026. Mineralys also presented new data on lorundrostat's efficacy and safety for resistant hypertension at scientific meetings.
Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer
Mineralys Therapeutics (MLYS) has announced the appointment of Jeffrey Munsie as its new chief legal officer. Munsie previously served as chief legal officer and Secretary at Orbital Therapeutics, where he was responsible for IP strategy, contracting, compliance, and transactions. This strategic hire comes as Mineralys Therapeutics advances its lorundrostat drug candidate and reports strong Q4 earnings.
Mineralys Grants Inducement Equity Awards to New Employee
Mineralys Therapeutics Inc. (Nasdaq: MLYS) has granted stock options and restricted stock units to a new non-executive employee as an inducement to join the company. These awards, issued under the company's 2025 Employment Inducement Incentive Award Plan, include 27,920 stock options and 20,940 restricted stock units, both vesting over four years. The biopharmaceutical company is focused on developing treatments for hypertension, with its lead drug candidate, lorundrostat, currently under regulatory review.
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics has appointed Jeffrey A. Munsie as its new Chief Legal Officer, bringing nearly 25 years of biopharma legal experience to the company. Munsie's expertise spans preclinical through commercialization stages, and he will be instrumental in strengthening legal and compliance capabilities as the company advances its product candidate, lorundrostat. In connection with his appointment, Munsie received inducement stock option and restricted stock unit awards.
Mineralys brings in veteran biotech lawyer as it advances lorundrostat
Mineralys Therapeutics has appointed Jeffrey A. Munsie as its Chief Legal Officer, bringing 25 years of biopharma legal experience to the company as it prepares for the potential commercialization of lorundrostat. Munsie received inducement equity awards, including stock options and restricted stock units, vesting over four years. This strategic hire aligns with Mineralys' ongoing efforts to build out its organizational and governance structure amidst regulatory progress for its lead drug candidate.
Mineralys Therapeutics appoints Jeffrey A. Munsie as chief legal officer
Mineralys Therapeutics has appointed Jeffrey A. Munsie as its chief legal officer. The company, focused on developing treatments for hypertension and chronic kidney disease, recently reported inducement awards and Q4 2025 earnings. This appointment follows recent activities such as an FDA acceptance of an NDA for lorundrostat and insider stock sales.
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics, a biopharmaceutical company specializing in hypertension treatments, has appointed Jeffrey A. Munsie as its Chief Legal Officer. Munsie brings 25 years of biopharma legal experience, most recently from Orbital Therapeutics, and will strengthen the company's legal and compliance capabilities as it advances its lead product candidate, lorundrostat. In connection with his appointment, Munsie received inducement stock options and restricted stock units.
Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA Acceptance - What's Changed
Mineralys Therapeutics (MLYS) saw its stock drop 8.1% despite a narrowed Q4 2025 net loss and the FDA's acceptance of its New Drug Application for lorundrostat, a hypertension treatment. This acceptance, with a PDUFA date of December 22, 2026, marks a significant step towards commercialization, although the company still faces risks associated with cash burn and reliance on a single asset. Analysts have varying revenue and earnings forecasts for Mineralys by 2029, with some being more bullish assuming lorundrostat clears regulatory hurdles and competition.
Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA Acceptance - What's Changed
Mineralys Therapeutics (MLYS) saw its net loss narrow in Q4 2025, and the FDA has accepted its New Drug Application for lorundrostat, targeting adult hypertension with a PDUFA date of December 22, 2026. Despite a more defined regulatory timeline, the company faces risks associated with reliance on a single asset and continued cash usage. Analysts project significant revenue and earnings growth by 2029 if lorundrostat clears regulatory hurdles and market entry challenges.
Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS
Hudson Bay Capital Management LP has acquired a new stake of 75,768 shares, valued at approximately $2.87 million, in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) during the third quarter. This investment is part of significant institutional interest, with key funds increasing or initiating positions, leading to institutional ownership of about 84.46%. Despite recent insider selling totaling $12.3 million, the company surpassed quarterly EPS estimates and holds a "Moderate Buy" consensus rating from analysts, with an average price target of $49.14 against its current trading price around $24.
Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised stock options for 417 shares at $15.44 each and simultaneously sold them at $25.65. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan, represent a small fraction of his total holdings, which stand at 76,140 shares after the sale. The filing indicates a routine portfolio adjustment rather than a significant sell-off.
Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions
Mineralys Therapeutics filed a Form 144 detailing proposed and past transactions in its common stock, including a broker-assisted cashless exercise of 417 shares on March 17, 2026. The filing also lists multiple dispositions by David Rodman during the first quarter of 2026, with the largest sale being 192,715 shares on January 5, 2026, for over $6.7 million. These entries serve as regulatory notices for proposed or recent sales by an affiliate.
Mineralys (MLYS) CMO exercises options, sells 20,406 shares under 10b5-1 plan
Mineralys Therapeutics' Chief Medical Officer, Rodman David Malcom, exercised stock options for 14,057 shares and subsequently sold 20,406 shares under a pre-arranged 10b5-1 trading plan. The transactions occurred on March 12-13, 2026, with sales executed at weighted-average prices between $25.77 and $27.92. Following these activities, he directly holds 76,140 shares of Mineralys Therapeutics common stock.
Holocene Advisors LP Buys Shares of 1,205,377 Mineralys Therapeutics, Inc. $MLYS
Holocene Advisors LP has acquired a significant new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS), purchasing over 1.2 million shares valued at approximately $45.7 million. This investment brings institutional ownership of Mineralys Therapeutics to about 84.46%. While analysts maintain a "Moderate Buy" rating with an average price target of $49.14, company insiders have been net sellers, offloading 363,325 shares in the past 90 days.
Mineralys Therapeutics (NasdaqGS:MLYS) Stock Forecast & Analyst Predictions
Mineralys Therapeutics (MLYS) is forecast to grow earnings and revenue by over 57% annually, with EPS also expected to increase by 57.2%. Analysts anticipate the company will remain unprofitable for the next three years despite significant future growth projections, largely driven by developments for its lead drug lorundrostat. Recent events include an FDA acceptance of its NDA for lorundrostat and multiple price target updates from analysts.
Mineralys Therapeutics CMO Sells Over 20,000 Shares
Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics (MLYS), sold 20,406 shares of company stock in multiple transactions on March 12 and 13, 2026. These sales, conducted under a Rule 10b5-1 trading plan, totaled $542,973. Following the transactions, Malcom now directly owns 76,140 shares.
New Mineralys hire gets stock options and RSUs vesting over four years
Mineralys Therapeutics announced it granted inducement equity awards to a new non-executive employee on March 16, 2026. This includes a stock option for 27,920 shares and restricted stock units (RSUs) for 20,940 shares, both vesting over four years. These grants were made under the company's 2025 Employment Inducement Incentive Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
HighVista Strategies LLC Boosts Position in Mineralys Therapeutics, Inc. $MLYS
HighVista Strategies LLC significantly increased its stake in Mineralys Therapeutics (NASDAQ:MLYS) by 39.8% to 209,829 shares, making it their eighth-largest holding. This comes as Mineralys Therapeutics has received positive news with the FDA accepting its NDA for lorundrostat, setting a PDUFA date of December 22, 2026, and beating Q4 earnings expectations. Despite some insider selling, institutional ownership remains high at 84.46%, and analysts maintain a "Moderate Buy" consensus with a target price around $49.14.
Farallon Capital Management LLC Purchases Shares of 1,673,053 Mineralys Therapeutics, Inc. $MLYS
Farallon Capital Management LLC recently acquired a new position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS), purchasing over 1.6 million shares valued at approximately $63.4 million. Other institutional investors also significantly increased their holdings in the company. Mineralys Therapeutics, whose stock opened at $26.19, has received a "Moderate Buy" consensus rating from analysts with an average target price of $49.14, and recently reported beating its quarterly earnings estimates.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of "Moderate Buy" from Brokerages
Mineralys Therapeutics (NASDAQ:MLYS) has received a consensus "Moderate Buy" rating from brokerages, with an average one-year price target of $49.14. This positive sentiment follows the FDA's acceptance of the NDA for lorundrostat, setting a PDUFA date of December 22, 2026, and stronger-than-expected Q4 results. Despite insider selling, institutional ownership remains high, and management is actively preparing for the commercial launch of its product.
Mineralys Therapeutics, Inc. $MLYS Shares Sold by 22NW LP
22NW LP significantly reduced its stake in Mineralys Therapeutics (MLYS) by 36% in the third quarter, selling over 200,000 shares, although the stock remains its fifth-largest holding. This comes amidst insider selling totaling $11.76 million last quarter, including notable sales by the CEO and an executive. Meanwhile, the FDA has accepted the NDA for lorundrostat with a PDUFA date of December 22, 2026, de-risking its potential approval and commercialization.
Integral Health Asset Management LLC Lowers Stake in Mineralys Therapeutics, Inc. $MLYS
Integral Health Asset Management LLC significantly reduced its stake in Mineralys Therapeutics, Inc. by 44.4% in the third quarter, despite the stock becoming its fourth-largest holding. This move comes as Mineralys Therapeutics has seen its NDA for lorundrostat accepted by the FDA with a PDUFA date set for December 22, 2026, and reported a stronger-than-expected Q4 EPS. However, insider selling has also occurred, with corporate insiders divesting shares worth over $11.7 million in the last 90 days.
Boothbay Fund Management LLC Increases Position in Mineralys Therapeutics, Inc. $MLYS
Boothbay Fund Management LLC significantly increased its stake in Mineralys Therapeutics (NASDAQ: MLYS) by 15.4% in the third quarter, making it their 5th largest holding. This comes as Mineralys' NDA for lorundrostat has been accepted by the FDA with a PDUFA date of December 22, 2026, and the company beat Q4 EPS estimates. Despite insider selling, institutional ownership remains high, and analysts maintain a "Moderate Buy" rating with a consensus price target of $49.14.
Mineralys Therapeutics (MLYS) makes progress with FDA for hypertension
The article reports that Mineralys Therapeutics (MLYS) has made progress with the FDA regarding its hypertension treatment. However, the provided content is incomplete, so no further details can be extracted.
Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026
Jefferies maintained a "Hold" rating for Mineralys Therapeutics, Inc. (MLYS) on March 13, 2026, while lowering its price target to $30. This decision reflects a cautious view on the stock's near-term prospects and limited upside without new catalysts, despite the company's B grade from Meyka AI. The market reacted with a -2.75% price drop following the announcement, prompting investors to reassess their positions and monitor future clinical updates for MLYS.
David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026
David Rodman, an insider at Mineralys Therapeutics (NASDAQ: MLYS), sold multiple tranches of common stock during Q1 2026, as detailed in a Form 144 SEC filing. The transactions, described as routine insider dispositions for liquidity, occurred between January 2, 2026, and March 12, 2026, and included both cash and broker-assisted cashless exercises of employee stock options. The largest single sale was 192,715 shares on January 5, 2026, contributing to gross proceeds of over $6.7 million from that transaction alone.
Jefferies cuts Mineralys Therapeutics price target on drug concerns
Jefferies has lowered its price target for Mineralys Therapeutics (MLYS) to $30 from $42, maintaining a Hold rating due to concerns that their drug, lorundrostat, is not sufficiently differentiated and that revenue estimates are too high. This adjustment follows the company's recent Q4 earnings report and comes despite other firms like BofA Securities and Stifel raising their price targets and reiterating Buy ratings on the stock. Mineralys Therapeutics is exploring various strategies for lorundrostat ahead of its December PDUFA date.
FDA accepts Mineralys (NASDAQ: MLYS) NDA for lorundrostat in hypertension
Mineralys Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for lorundrostat, a treatment for hypertension, and set a PDUFA target decision date of December 22, 2026. The company also reported its fourth-quarter and full-year 2025 financial results, showing a significantly strengthened cash position of $656.6 million, expected to fund operations into 2028, and a narrowed net loss. This marks a pivotal step towards potential commercialization for lorundrostat following successful clinical trials.
Atika Capital Management LLC Buys New Shares in Mineralys Therapeutics, Inc. $MLYS
Atika Capital Management LLC has acquired 174,000 new shares of Mineralys Therapeutics (NASDAQ:MLYS) in Q3, valued at approximately $6.6 million. Despite recent insider selling totaling $11.76 million, institutional investors hold a significant 84.46% stake in the company. Analysts maintain a "Moderate Buy" consensus rating for MLYS, with an average price target of $47.43.
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Mineralys Therapeutics (Nasdaq: MLYS) announced its fourth-quarter and full-year 2025 financial results, highlighting the FDA's acceptance of their New Drug Application (NDA) for lorundrostat to treat hypertension, with a PDUFA target date of December 22, 2026. The company reported significant clinical progress in 2025, including successful clinical trials for lorundrostat, which demonstrated meaningful blood pressure reduction and a favorable safety profile. Financially, Mineralys ended 2025 with $656.6 million in cash, cash equivalents, and investments, projecting sufficient funds into 2028.
Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)
Mineralys Therapeutics (MLYS) reported Q4 EPS of (40c), exceeding the consensus estimate of (52c). CEO Jon Congleton highlighted 2025 as a "transformational year" due to significant clinical progress, key regulatory milestones, and the FDA's acceptance of their NDA for lorundrostat, a treatment for inadequately controlled hypertension. The company anticipates working with the FDA towards potential approval and commercialization.
Mineralys Therapeutics 10-K: $0 Revenue, $(2.29) EPS
Mineralys Therapeutics (MLYS) reported zero product revenue and a net loss per share of $(2.29) for the year ended December 31, 2025, reflecting no approved products for sale. Despite financial losses, the company is progressing towards commercialization with its NDA for lorundrostat accepted by the FDA with a PDUFA date of December 22, 2026, positive Phase 3 clinical results, and sufficient cash runway for at least 12 months. They are also scaling up operations to support late-stage development and pre-launch activities.
MINERALYS THERAPEUTICS ($MLYS) Releases Q4 2025 Earnings
MINERALYS THERAPEUTICS ($MLYS) announced its Q4 2025 earnings, reporting -$0.40 per share, which surpassed estimates. The company also posted $0 revenue, meeting expectations. The article details recent insider trading activities, significant hedge fund movements, and analyst ratings and price targets for MLYS.
